These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21519219)

  • 21. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ticagrelor: from discovery to Phase III clinical trial.
    Siller-Matula JM; Jilma B
    Future Cardiol; 2010 Nov; 6(6):753-64. PubMed ID: 21142630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ticagrelor: positive, negative and misunderstood properties as a new antiplatelet agent.
    Steiner JB; Wu Z; Ren J
    Clin Exp Pharmacol Physiol; 2013 Jul; 40(7):398-403. PubMed ID: 23590223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.
    Tomasello SD; Tello-Montoliu A; Angiolillo DJ
    Expert Opin Investig Drugs; 2011 Jan; 20(1):119-33. PubMed ID: 21143003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention.
    Yokoi H; Kimura T; Isshiki T; Ogawa H; Ikeda Y
    Thromb Res; 2012 May; 129(5):623-8. PubMed ID: 22178576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ticagrelor: the silence of the platelets.
    Laine M; Paganelli F; Bonello L
    Expert Opin Pharmacother; 2013 Feb; 14(2):151-3. PubMed ID: 23294190
    [No Abstract]   [Full Text] [Related]  

  • 28. Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.
    Höchtl T; Tentzeris I; Schrör K; Huber K
    Fundam Clin Pharmacol; 2012 Feb; 26(1):2-10. PubMed ID: 21831128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ticagrelor Versus Clopidogrel in Comatose Survivors of Out-of-Hospital Cardiac Arrest Undergoing Percutaneous Coronary Intervention and Hypothermia: A Randomized Study.
    Steblovnik K; Blinc A; Mijovski MB; Fister M; Mikuz U; Noc M
    Circulation; 2016 Dec; 134(25):2128-2130. PubMed ID: 27994027
    [No Abstract]   [Full Text] [Related]  

  • 30. Ticagrelor: the first novel reversible P2Y(12) inhibitor.
    Htun WW; Steinhubl SR
    Expert Opin Pharmacother; 2013 Feb; 14(2):237-45. PubMed ID: 23268703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].
    Schreiber P; Fauchère I; Wyss C
    Praxis (Bern 1994); 2014 Sep; 103(18):1049-58. PubMed ID: 25183612
    [No Abstract]   [Full Text] [Related]  

  • 32. Ticagrelor: a novel reversible oral antiplatelet agent.
    Nawarskas JJ; Clark SM
    Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ticagrelor for acute coronary syndromes.
    Bansilal S; Bonaca MP; Sabatine MS
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1473-84. PubMed ID: 24147518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
    Gurbel PA; Bliden KP; Butler K; Antonino MJ; Wei C; Teng R; Rasmussen L; Storey RF; Nielsen T; Eikelboom JW; Sabe-Affaki G; Husted S; Kereiakes DJ; Henderson D; Patel DV; Tantry US
    Circulation; 2010 Mar; 121(10):1188-99. PubMed ID: 20194878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiplatelet options for secondary prevention in acute coronary syndromes.
    Silvain J; Cayla G; O'Connor SA; Collet JP; Montalescot G
    Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1403-15. PubMed ID: 22059790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes.
    Berger JS
    Am J Cardiol; 2013 Sep; 112(5):737-45. PubMed ID: 23751937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
    Norgard NB; Dinicolantonio JJ
    Postgrad Med; 2013 Jul; 125(4):91-102. PubMed ID: 23933898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ticagrelor. Acute coronary syndromes: nothing new.
    Prescrire Int; 2011 Oct; 20(120):229-33. PubMed ID: 21970081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: focus on adenosine diphosphate receptor inhibitors.
    Ogawa H; Hokimoto S; Kaikita K; Yamamoto K; Chitose T; Ono T; Tsujita K
    J Cardiol; 2011 Jul; 58(1):6-17. PubMed ID: 21530174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.